ScopeSynnovis Analytics
Official name: Synnovis Analytics LLP
100 capabilities
Verified Oct 2026
One of 2,018 in United Kingdom
Send one structured enquiry and we chase the reply for you. No cold email, no chasing.
Details
TThe Laboratory for Molecular Haemato-Oncology, Kings College Hospital, The Rayne Institute 123, Coldharbour Lane
London SE5 9RS , United Kingdom
London SE5 9RS , United Kingdom
Accreditation
Active
UKAS
9597
synnovis.co.uk
Prefer to enquire through us? Send an enquiry
Accreditation Details
Accreditation Body
UKAS
Number
9597
Status
ActiveAccreditation is granted under EU Regulation 765/2008 and assessed against ISO/IEC 17025. Data sourced from official UKAS records.
Download Scope PDFOther locations
Synnovis Analytics
King's College Hospital
Synnovis Analytics
Guy's Hospital
Synnovis Analytics
King’s College Hospital
Synnovis Analytics
London
Synnovis Analytics
London
Synnovis Analytics
London
Synnovis Analytics
London
Synnovis Analytics
Denmark Hill
Synnovis Analytics
Guy's Hospital
Synnovis Analytics
9 King’s Head Yard
Synnovis Analytics
London
Synnovis Analytics
London
Synnovis Analytics
Denmark Hill
Test Capabilities (100)
| Standard Reference | Description | Category |
|---|---|---|
| MEASUREMENT | Measurement | Electrical |
| CD4 | CD4 | Food Safety Testing |
| Bone Marrow | CD300e | Bone Marrow | CD300e | Hematology |
| Bone Marrow | CD45AML 4 Antigen | Bone Marrow | CD45AML 4 Antigen | Hematology |
| CD34 | CD34 | Hematology |
| Haematology/Immunophenoty ping examinations for the purpose of clinical diagnosis | Haematology/Immunophenoty ping examinations for the purpose of clinical diagnosis | Hematology |
| Haematology/Immunophenoty ping examinations for the purpose of clinical diagnosis Immunophenotyping for Myelodisplastic Syndrome (MDS) assessment: CD34 | Haematology/Immunophenoty ping examinations for the purpose of clinical diagnosis Immunophenotyping for Myelodisplastic Syndrome (MDS) assessment: CD34 | Hematology |
| Haematology/Immunophenoty ping examinations for the purpose of clinical diagnosis Testing for Paroxysmal Nocturnal Haemoglobinuria (PNH): WBC: CD157 | Haematology/Immunophenoty ping examinations for the purpose of clinical diagnosis Testing for Paroxysmal Nocturnal Haemoglobinuria (PNH): WBC: CD157 | Hematology |
| Immunophenotyping for diagnosis of acute leukemia: Acute “Screen”: CD8 | Immunophenotyping for diagnosis of acute leukemia: Acute “Screen”: CD8 | Hematology |
| RBC | RBC | Hematology |
| B Cells | CD79a | B-Cells | CD79a | Histopathology / Cytology |
| CD30 | CD30 | Histopathology / Cytology |
| Chronic Lymphocytic Leukaemia | Chronic Lymphocytic Leukaemia | Histopathology / Cytology |
| AML Tube 1 | AML Tube 1 | Immunology / Serology |
| AML Tube 2 | AML Tube 2 | Immunology / Serology |
| B-ALL: TdT | B-ALL: | 8 colours | Immunology / Serology |
| CD10 | CD10 | Immunology / Serology |
| CD117 | CD117 | Immunology / Serology |
| CD11b | CD11b | Immunology / Serology |
| CD13 | CD13 | Immunology / Serology |
| CD138 | CD138 | Immunology / Serology |
| CD14 | CD14 | Immunology / Serology |
| CD15 | CD15 | Immunology / Serology |
| CD16 | CD16 | Immunology / Serology |
| CD19 | CD19 | Immunology / Serology |
| CD1A | CD1a | Immunology / Serology |
| CD2 | CD2 | Immunology / Serology |
| CD20 | CD20 | Immunology / Serology |
| CD25 | CD25 | Immunology / Serology |
| CD3 | CD3 | Immunology / Serology |
| CD33 | CD33 | Immunology / Serology |
| CD36 | CD36 | Immunology / Serology |
| CD38 | CD38 | Immunology / Serology |
| CD43 | CD43 | Immunology / Serology |
| CD45 | CD45 | Immunology / Serology |
| CD5 | CD5 | Immunology / Serology |
| CD56 | CD56 | Immunology / Serology |
| CD64 | CD64 | Immunology / Serology |
| CD7 | CD7 | Immunology / Serology |
| CD71 | CD71 | Immunology / Serology |
| CD79b | CD79b | Immunology / Serology |
| CD8 | CD8 | Immunology / Serology |
| FLAER | FLAER | Immunology / Serology |
| IREM2 | IREM2 | Immunology / Serology |
| KAPPA | Kappa | Immunology / Serology |
| LAMBDA | Lambda | Immunology / Serology |
| T-ALL | T-ALL: | 6 colours | Immunology / Serology |
| BCR-ABL P190 | BCR-ABL P190 | Molecular Diagnostics / PCR |
| BCR-ABL P210 | BCR-ABL P210 | Molecular Diagnostics / PCR |
| BCR-ABL Tyrosine Kinase | BCR-ABL Tyrosine Kinase | Molecular Diagnostics / PCR |
| BRAF V600E | BRAF V600E | Molecular Diagnostics / PCR |
| Chimerism monitoring including subset monitoring (CD3, CD15 & CD19) measurement | Chimerism monitoring including subset monitoring (CD3, CD15 & CD19) measurement | Molecular Diagnostics / PCR |
| Detection of BCR-ABL1 fusion transcripts e13a2, e13a3, e14a2, e14a3, e1a2, e1a3, e19a2, e19a3, e6a2, e6a3, e8a2, e8a3, e18a2 and e18a3 | Detection of BCR-ABL1 fusion transcripts e13a2, e13a3, e14a2, e14a3, e1a2, e1a3, e19a2, e19a3, e6a2, e6a3, e8a2, e8a3, e18a2 and e18a3 | Molecular Diagnostics / PCR |
| FLT3 TKD, FLT3 ITD and NPM1 mutation analysis Cytogenetics Haemto- Oncology activities for the purpose of clinical diagnosis | FLT3 TKD, FLT3 ITD and NPM1 mutation analysis Cytogenetics Haemto- Oncology activities for the purpose of clinical diagnosis | Molecular Diagnostics / PCR |
| JAK2 Exon 12 | JAK2 Exon 12 | Molecular Diagnostics / PCR |
| JAK2 V617F | JAK2 V617F | Molecular Diagnostics / PCR |
| PML-RARA | PML-RARA | Molecular Diagnostics / PCR |
| AML-ETO | AML-ETO | Other |
| Acute Leukemia Orientation | Acute Leukemia Orientation | Other |
| Acute myeloid leukaemia | Acute myeloid leukaemia | Other |
| Analysis of next generation sequencing measurement | Analysis of next generation sequencing measurement | Other |
| B-cell follow on: Tube 1: CD19 CD81 CD23 CD79b CD10 CD200 CD43 CD45 Tube 2: CD19 CD103 CD123 CD11c CD25 ROR1 CD45 measurement | B-cell follow on: Tube 1: CD19 CD81 CD23 CD79b CD10 CD200 CD43 CD45 Tube 2: CD19 CD103 CD123 CD11c CD25 ROR1 CD45 measurement | Other |
| Backbone: CD34 | Backbone: CD34 | Other |
| Bone Marrow | Tube 3: | Bone Marrow | Tube 3: | Other |
| CALR | CALR | Other |
| CD123 | Human CD123 | Other |
| CD19 measurement | CD19 measurement | Other |
| CD235a measurement | CD235a measurement | Other |
| CD3 cytCD3 | CD3 cytCD3 | Other |
| CD45 measurement | CD45 measurement | Other |
| CD66c | CD66c | Other |
| CD99 | CD99 | Other |
| Classification of Haematolymphoid Tumours (5 th edition) | Classification of Haematolymphoid Tumours (5 th edition) | Other |
| Constitutional analysis to confirm karyotyping findings measurement | Constitutional analysis to confirm karyotyping findings measurement | Other |
| Cyt Kappa / Cyt Lambda | Cyt Kappa / Cyt Lambda | Other |
| Cytogenetic analysis for the purpose of clinical diagnosis | Cytogenetic analysis for the purpose of clinical diagnosis | Other |
| Detection of diagnostically and prognostically relevant cytogenetic abnormalities defined in the WHO | Detection of diagnostically and prognostically relevant cytogenetic abnormalities defined in the WHO | Other |
| Diagnosis | diagnosis: | Documented in-house methods to | Other |
| Diagnosis and therapy monitoring | Diagnosis and therapy monitoring | Other |
| Diagnosis and therapy monitoring measurement | Diagnosis and therapy monitoring measurement | Other |
| HLADR | HLADR | Other |
| Haematology/Immunophenoty ping examinations for the purpose of clinical diagnosis Immunophenotyping for Chronic T and B lymphoproliferative disorders: LST Tube: CD19 | Haematology/Immunophenoty ping examinations for the purpose of clinical diagnosis Immunophenotyping for Chronic T and B lymphoproliferative disorders: LST Tube: CD19 | Other |
| Haematology/Immunophenoty ping examinations for the purpose of clinical diagnosis Tube 5: CD61/CD42 CD123 CD7 CD4 | Haematology/Immunophenoty ping examinations for the purpose of clinical diagnosis Tube 5: CD61/CD42 CD123 CD7 CD4 | Other |
| INV16 | INV16 | Other |
| Immunophenotyping for the diagnosis of Plasma cell disorders: CD27 | Immunophenotyping for the diagnosis of Plasma cell disorders: CD27 | Other |
| Iron deposits haemosiderin | Iron deposits haemosiderin | Other |
| JAK2 Exon 14 | JAK2 Exon 14 | Other |
| Karyotyping | Karyotyping | Other |
| MPL | MPL; | Other |
| Minimal Residual Disease (MRD) assessment of: B-acute lymphoblastic leukaemia: CD58 | Minimal Residual Disease (MRD) assessment of: B-acute lymphoblastic leukaemia: CD58 | Other |
| Molecular Haemto-Oncology activities for the purpose of clinical diagnosis | Molecular Haemto-Oncology activities for the purpose of clinical diagnosis | Other |
| Myeloproliferative Neoplasms | Myeloproliferative Neoplasms | Other |
| NG2 | NG2 | Other |
| ROR 1 | ROR 1 | Other |
| SNP Array Karyotyping measurement | SNP Array Karyotyping measurement | Other |
| T-cell follow on: Tube 1: CD57 | T-cell follow on: Tube 1: CD57 | Other |
| TCR Gamma/Delta | TCR Gamma/Delta | Other |
| TCR gamma delta | TCR gamma delta | Other |
| TDT | TDT | Other |
| Tube: MPO | Tube: MPO | Other |
Send an Enquiry
Request a quote, ask about capacity, or discuss your testing requirements directly with this lab.